Last updated 2025-03-17 20:26:02 (EDT)

Fundamental Analysis

By analyzing seasonally adjusted quarterly revenue, one can gauge the trend of stock. However, please note that stock prices can sometimes lead fundamental data, so it should be accompanied by other leading indicators for better judgment.

Quarterly Revenue Trend tooltip
Quarterly Revenue (USD)Price (USD)23,181,88840,000,00060,000,00080,000,000100,000,000120,000,000140,000,000160,000,000180,000,000200,000,00081626364656667686962017-01-032019-01-012021-01-012023-01-012025-03-17Seasonally Adjusted Quarterly RevenuePrice

Quarter-over-Quarter Growth Rate
of Seasonally Adjusted Quarterly Revenue

-0.6%


As of 2024-12-31

Basic Information

Basic information of individual stocks, as well as their respective sectors and industries.

Company Introduction

Business Overview

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

Industry

Sector
Healthcare
Industry
Biotechnology

Disclaimer

1. The information provided is for reference only and does not constitute any guarantee of profits or specific stock and price point recommendations.

2. The information is not complete; for comprehensive data, please refer to the relevant websites.

3. All stock market data analyses are subject to survivorship bias.

warning